Navigation Links
Experimental Vaccine Shows Promise for Lung Cancer: Study

MONDAY, Oct. 24 (HealthDay News) -- New research suggests that physicians may be able to strengthen the power of chemotherapy in patients with the most common form of lung cancer by adding a cancer vaccine to the treatment.

The combined treatment for non-small cell lung cancer was tested in a phase 2 study and still has to go through more research, as experimental drugs go through three phases of study. Although the rate of serious side effects was somewhat higher in those who received both treatments compared to chemotherapy alone, this new approach seems feasible, the study authors said.

Commenting on the study, Srikumar Chellappan, chair of the department of tumor biology and scientific director of the National Functional Genomics Center at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Fla., said that the research is promising and the treatment could become a new strategy.

Chellappan, who was not involved with the study but is familiar with the findings, noted there are caveats. "It should be pointed out that the increases in overall survival and progression-free survival are not dramatic, but any increase is very welcome, considering that the patients are in an advanced stage of cancer."

Patients with advanced non-small cell lung cancer have very low survival rates because of the spread of cancer to various organs in the body, such as the brain, Chellappan noted.

Currently, patients with advanced disease are treated with chemotherapy. In the study, published online Oct. 22 in The Lancet Oncology, Elisabeth Quoix from the University of Strasbourg in France and colleagues assigned 148 patients in the advanced stages of non-small cell lung cancer to either receive the experimental cancer vaccine called TG4014 in combination with chemotherapy or receive chemotherapy alone.

After six months, the cancer in 43 percent of those given the combination treatment hadn't progressed compared to 35 percent of those who took chemotherapy alone. The combo treatment was especially beneficial in a subgroup of patients who had a normal number of a type of immune response cells called "natural killer cells" upon entering the study, the researchers noted in a journal news release.

The rate of serious side effects was 52 percent in those given the combo treatment and 47 percent in those who received chemotherapy alone.

Non-small cell lung cancer is the number one cause of cancer death worldwide, and nearly half of these patients already have advanced disease by the time they are diagnosed, the authors noted in the news release.

More information

For more about lung cancer, visit the U.S. National Library of Medicine.

-- Randy Dotinga

SOURCES: Srikumar Chellappan, Ph.D., chair, department of tumor biology and scientific director, National Functional Genomics Center, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Fla.; Oct. 22, 2011, The Lancet Oncology, online

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Drug Offers Hope for Cystic Fibrosis Patients
2. Experimental Vaccine Shields Monkeys Against Ebola
3. Experimental targeted therapy shows early promise against medulloblastomas
4. Experimental nonsteroidal treatment of asthma shows promise
5. Experimental obesity drug avoids brain effects that troubled predecessors
6. Experimental treatments for cocaine addiction may prevent relapse
7. Experimental TB Test Called Fast and Accurate
8. Experimental Drug Shows Promise for Bone Marrow Disorder
9. Experimental Leukemia Drug Proves a Slam Dunk
10. Experimental Test May Spot Prostate Cancer Earlier, More Accurately
11. Experimental Drug Aids Kids With Nervous System Tumor
Post Your Comments:
Related Image:
Experimental Vaccine Shows Promise for Lung Cancer: Study 
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   ... Spaulding Rehabilitation Network,s Dean Center for Tick ... Physical Medicine and Rehabilitation, MIT Hacking Medicine, University ... for Innovation, today announced the five finalists of ... for Lyme disease.  More than 100 scientists, clinicians, ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
Breaking Medicine Technology: